A detailed history of Schonfeld Strategic Advisors LLC transactions in Bio Atla, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 33,200 shares of BCAB stock, worth $54,116. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,200
Holding current value
$54,116
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.37 - $3.92 $45,484 - $130,144
33,200 New
33,200 $45,000
Q3 2022

Nov 14, 2022

SELL
$2.94 - $11.87 $92,022 - $371,531
-31,300 Reduced 67.75%
14,900 $115,000
Q2 2022

Aug 15, 2022

SELL
$2.13 - $5.38 $57,723 - $145,798
-27,100 Reduced 36.97%
46,200 $132,000
Q1 2022

May 16, 2022

BUY
$4.38 - $18.78 $321,054 - $1.38 Million
73,300 New
73,300 $367,000
Q4 2021

Feb 14, 2022

SELL
$19.0 - $30.95 $178,068 - $290,063
-9,372 Closed
0 $0
Q3 2021

Nov 16, 2021

BUY
$29.44 - $43.74 $275,911 - $409,931
9,372 New
9,372 $276,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $59.2M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.